- Home
- MIRM vs HAYW Comparison
MIRM vs HAYW Comparison
Compare MIRM & HAYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- HAYW
- Stock Information
- Founded
- MIRM 2018
- HAYW 1925
- Country
- MIRM United States
- HAYW United States
- Employees
- MIRM N/A
- HAYW N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- HAYW Electronic Components
- Sector
- MIRM Health Care
- HAYW Technology
- Exchange
- MIRM Nasdaq
- HAYW Nasdaq
- Market Cap
- MIRM 3.8B
- HAYW 3.3B
- IPO Year
- MIRM 2019
- HAYW 2021
- Fundamental
- Price
- MIRM $72.65
- HAYW $16.97
- Analyst Decision
- MIRM Strong Buy
- HAYW Hold
- Analyst Count
- MIRM 11
- HAYW 5
- Target Price
- MIRM $79.00
- HAYW $17.33
- AVG Volume (30 Days)
- MIRM 560.3K
- HAYW 2.0M
- Earning Date
- MIRM 11-04-2025
- HAYW 10-29-2025
- Dividend Yield
- MIRM N/A
- HAYW N/A
- EPS Growth
- MIRM N/A
- HAYW 44.13
- EPS
- MIRM N/A
- HAYW 0.62
- Revenue
- MIRM $429,161,000.00
- HAYW $1,099,855,000.00
- Revenue This Year
- MIRM $53.14
- HAYW $5.84
- Revenue Next Year
- MIRM $19.83
- HAYW $5.39
- P/E Ratio
- MIRM N/A
- HAYW $27.39
- Revenue Growth
- MIRM 62.33
- HAYW 9.66
- 52 Week Low
- MIRM $36.88
- HAYW $11.10
- 52 Week High
- MIRM $78.55
- HAYW $17.73
- Technical
- Relative Strength Index (RSI)
- MIRM 52.77
- HAYW 66.47
- Support Level
- MIRM $68.34
- HAYW $15.24
- Resistance Level
- MIRM $71.96
- HAYW $17.73
- Average True Range (ATR)
- MIRM 2.53
- HAYW 0.47
- MACD
- MIRM -0.13
- HAYW 0.21
- Stochastic Oscillator
- MIRM 56.54
- HAYW 73.70
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About HAYW Hayward Holdings Inc.
Hayward Holdings is a leading manufacturer of energy-efficient swimming pool equipment and pool automation systems. The company offers a wide range of pool equipment, including pumps, filters, heaters, LED lights, and sanitization. Headquartered in Charlotte, North Carolina, the company has around 2,000 full-time employees. Hayward generated approximately $1.1 billion in revenue in 2024.